title: Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma.
abstract: A randomised double-blind placebo-controlled study was designed to evaluate the effects of a semisynthetic macrolide antibiotic, clarithromycin, on bronchial hyperresponsiveness to methacholine in patients with a diagnosis of asthma. Adult asthma patients undergoing treatment with budesonide 400 microg b.i.d. and salbutamol 200 microg p.r.n. less than twice weekly were studied. Arm A (16 males/six females, aged 48 +/- 16 yrs) received clarithromycin 250 mg b.i.d. for 8 weeks, arm B (eight males/12 females, aged 42 +/- 12 yrs) clarithromycin 250 mg t.id. and arm C (six males/15 females, aged 41 +/- 16 yrs) placebo dextrose tablets. Bronchial hyperresponsiveness was quantified by measurement of the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD20). Median (interquartile range) PD20 in the three groups before and after treatment with clarithromycin were: arm A: 0.3 (0.1-1) and 1.3 (0.6-2) mg; arm B: 0.4 (0.1-0.9) and 2 (2-2) mg; and arm C: 0.4 (0.1-0.9) and 0.3 (0.1-0.6) mg, respectively. Serum free cortisol levels were determined and remained unchanged from baseline in the clarithromycin-treated patients. It is concluded that clarithromycin reduces the degree of bronchial hyperresponsiveness in patients with asthma.
authors.affiliation: 10th Respiratory Dept, Athens Chest Hospital, Athens, Greece. ealexop@yahoo.com
authors.forename: E
authors.initials: E
authors.lastname: Kostadima
authors.forename: S
authors.initials: S
authors.lastname: Tsiodras
authors.forename: E I
authors.initials: EI
authors.lastname: Alexopoulos
authors.forename: A G
authors.initials: AG
authors.lastname: Kaditis
authors.forename: I
authors.initials: I
authors.lastname: Mavrou
authors.forename: N
authors.initials: N
authors.lastname: Georgatou
authors.forename: A
authors.initials: A
authors.lastname: Papamichalopoulos
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D016085:Bronchoconstrictor Agents; D017291:Clarithromycin / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D016210:Methacholine Chloride; D008875:Middle Aged; D013147:Spirometry; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D016085:Bronchoconstrictor Agents; D016210:Methacholine Chloride; D017291:Clarithromycin